|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2016
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XX40
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
|
|
gptkbp:contraindication
|
hypersensitivity
severe liver impairment
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:drug_interactions
|
strong CYP3 A inducers
strong CYP3 A inhibitors
|
|
gptkbp:formulation
|
venetoclax 10 mg
venetoclax 100 mg
venetoclax 200 mg
venetoclax 50 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Venclexta
|
|
gptkbp:ingredients
|
gptkb:venetoclax
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_a_guide_for
|
ASCO guidelines
NICE guidelines
ESMO guidelines
NCCN guidelines
|
|
gptkbp:manufacturer
|
gptkb:Abb_Vie
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
BCL-2 inhibitor
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:patient_population
|
adults
elderly
patients with AML
patients with CLL
|
|
gptkbp:research_areas
|
oncology
hematology
pharmacology
clinical research
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
clinical trials
adverse event reporting
post-marketing surveillance
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
nausea
diarrhea
thrombocytopenia
|
|
gptkbp:structure
|
C22 H25 Cl N2 O4 S
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:Abb_Vie
|
|
gptkbp:bfsLayer
|
4
|